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Materials and methods. The DAM level was measured by the classical thiobarbituric acid 
method, described by Vladimirov Iu. (1972), in the hepatic homogenate and erythrocytes of 
white laboratory rats subjected to muscle ischemia (240 min) and reperfusion (90 min) 
compared to control (240 min. ischemia) and healthy animals.  
Results. Prolonged ischemia (240 min) induced an insignificant (p> 0.05) increase in the level 
of DAM in both the hepatic homogenate (+7%) and in the erythrocyte hemolysate (+9%) in 
the experimental animals compared to the healthy ones. Removal of the causal factor and 
reperfusion (90 min) of the compressed muscle tissue did not change the DAM values in the 
hepatic homogenate, but produced a statistically significant decrease, up to values below those 
found in the control animals, in erythrocytes (-25%, p<0.01). Thus, long-lasting ischemia is 
associated with an insignificant increase in the end product of lipid peroxidation, which 
possible confirms the sufficient antioxidant capacity of the liver and erythrocytes, which in the 
case of blood cells is surpassed by the oxidative explosion conditioned by the reperfusion and 
the entry of oxygen.   
Conclusions. Statistically insignificant changes of DAM content in the liver and erythrocytes 
of animals with oxidative stress triggered by ischemia/reperfusion attest minor value of DAM 
as a marker of oxidative stress at late stages of the pathological process.  
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Introduction. Hepatic fibrosis is a worldwide health issue, whose prognosis; management and 
potential treatment depend on establishing the accurate diagnosis according to the progression 
of the disease. Modern medicine studies efficient, safe and non-invasive methods for the 
assessment of hepatic fibrosis, such as serum biomarkers and imaging techniques: FibroScan 
elastometry, MRI, ARFI.  
Aim of the study. Identification and study of the non-invasive methods for the diagnosis of 
hepatic fibrosis  
Materials and methods. A bibliographic study of scientific literature from 2009-2020 based 
on Biomed Central, Bio Predictive, ACS Publications data bases was done, with the following 
search words – hepatic fibrosis, non-invasive diagnosis, fibrotest, biomarker of fibrosis.  
Results. Serum biomarkers, used for the assessment of hepatic fibrosis, are classified in: direct 
biomarkers – Procollagen type I carboxy-terminal peptide (PICP), Procollagen type III amino-
terminal peptide (PIIINP), matrix metalloproteinases (MMPs), tissue inhibitors of matrix 
metalloproteinases (TIMPs), hyaluronic acid (HA), transforming growth factor β1 (TGFβ1), 
laminin, connective tissue growth factor (CTGF); and indirect biomarkers – AST/ALT ratio, 
coagulation factors, platelet count, γ2-macroglobulin, γ2-globulin, γ-globulin, apolipoprotein 
A1, GGT, total bilirubin. These serum biomarkers are combined in non-invasive scores such 
as APRI, FibroTest, FIB-4. Transient Ultrasound Elastography or FibroScan measures liver 
stiffness (elasticity) and allows determining the stage of hepatic fibrosis according to 
METAVIR score: F1, F2, F3, and F4. MRI can be used to measure hepatic stiffness, and at the 
same time other associated pathologies.  
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Conclusions. Management and individualized treatment of hepatic fibrosis depend on 
establishing an accurate stage diagnosis. Non-invasive methods, serum biomarkers and 
imaging techniques allow to determine a correct diagnosis and at the same time to minimize 
the complications. FibroTest, FibroScan and APRI score are methods that showed the highest 
clinical efficiency. However, recent studies are focused on identifying the correlation between 
tissue modifications, the results of serum biomarkers and FibroTest, FibroScan and APRI 
score.   
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Introduction. Cholecystokinin (CCK) is a peptide hormone that, together with secretin and 
gastrin, forms the triad of intestinal hormones. Due to the receptors, which are expressed in 
different tissues, and to the diversity of the subgroups of the cholecystokinin family peptides 
that activates them, CCK acts on different organs and systems.  
Aim of the study. Identification and study of the biochemical and physiological effects of the 
subgroups of the CCK peptides family and of their role in maintaining homeostasis and 
viability of the human organism.  
Materials and methods. A bibliographic study of the specialized literature present in the 
databases PubMed, MeSH, Internet Archive, IUPHAR/BPS, from 2010-2020 was performed, 
using the search words cholecystokinin, CCK receptors, expression of CCK receptors, 
cholecystokinin-like peptides, physiology of the Gastrointestinal Tract.  
Results. There are two types of CCK receptors: CCK-A (CCK1 "Alimentary") and CCK-B 
(CCK2 "Brain"). CCK-A receptors are located in the gall bladder where stimulates its 
contractions, in the intestinal parietal mucosa where via somatostatin inhibits gastric acid 
secretion, in the nervous system where directly or indirectly, through dopaminergic processes, 
it modulates the behavior in general and eating behavior in particular. CCK-B receptors are 
predominantly in the CNS where they modulate anxiety, analgesia and neuroleptic activities. 
CCK-B receptors also have been identified in the pancreas where they stimulate the secretion 
of enzymes. It has been shown that pancreas-responsible neurons release CCK-8 and CCK-5, 
which subsequently produce effects. Moreover, CCK via acetylcholine activates 
parasympathetic neurons, therefore increasing blood supply to the stomach and increasing 
motility. At the thyroid level, CCK-8 stimulates normal growth and C-cell proliferation.   
Conclusions. The expression of CCK at the level of different organs determines a wide range 
of various effects, involved in normal metabolic and physiological processes, which ensures 
the maintenance of homeostasis and viability of organs and tissues. Knowledge of the 
pleiotropic effects of the CCK family peptides and the receptors involved in their development 
opens new possibilities for addressing the nutritional disorders and functional diseases of the 
gastrointestinal tract, as well as of intervention in some processes in the nervous system 
associated with chronic pain, anxiety and depression.  
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